Programmed cell death protein ligand 1 (PD-L1) blockade has emerged as a key therapy for advanced non-small cell lung cancer (NSCLC). Unfortunately, one of the key barriers in the treatment is the acquired resistance to PD-L1, even though after the initial response to the treatment, more than 60% of the patients develop acquired resistance. In a study published in the Cancer Cell journal by Memon et al. (2024), a cohort of 1,201 patients with NSCLC was analyzed to evaluate the relapse mechanism. They identified subtypes with persistent or upregulated interferon γ (IFNγ) signaling, immune dysfunction, and antigen presentation defects. Murine models exposed to chronic IFNγ recapitulated these features, highlighting that a chronically inflamed microenvironment drives resistance. These insights underscore the need for adaptive therapies that dynamically target evolving tumor-immune interactions.

Aim: This study aimed to explore the correlation between peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and diabetic kidney disease (DKD) susceptibility in the Han Chinese population.

Methods: The distribution of Gly482Ser (rs8192678) and its relationship with blood PGC-1α messenger RNA (mRNA) expression were examined in healthy volunteers, patients with type 2 diabetes mellitus (T2DM), and those with DKD. The single-nucleotide polymorphism was genotyped using a DNA extraction kit and TaqMan-minor groove binder (MGB) probe real-time polymerase chain reaction.

Results: We enrolled 574 subjects: 212 healthy controls, 186 with T2DM, and 176 with DKD. The rs8192678 AA genotype was more frequent in controls than in T2DM or DKD groups (P < 0.001). Under additive, dominant, and recessive models, the GG genotype was linked to higher T2DM risk after age and sex adjustment (P < 0.001), but not to progression from T2DM to DKD. PGC-1α mRNA levels were also higher in AA carriers than in GG carriers across all groups (P < 0.05).

Conclusion: Our study identifies the G allele of PPARGC1A rs8192678 as a risk factor for T2DM, but its role in DKD is context-dependent. Although not a risk factor in the general T2DM population, this allele is linked to higher DKD risk specifically in patients with normal triglyceride levels. This association was driven by the GA and AA genotypes, not the GG genotype, highlighting the complex interplay between genetics and metabolic state in DKD.